Cargando…
ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1–Infected, Antiretroviral Therapy–Naive Subjects
Background. Dolutegravir (DTG), a once-daily, human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, was evaluated for distribution and antiviral activity in cerebrospinal fluid (CSF). Methods. ING116070 is an ongoing, single-arm, open-label, multicenter study in antiretroviral therapy–nai...
Autores principales: | Letendre, Scott L., Mills, Anthony M., Tashima, Karen T., Thomas, Deborah A., Min, Sherene S., Chen, Shuguang, Song, Ivy H., Piscitelli, Stephen C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166983/ https://www.ncbi.nlm.nih.gov/pubmed/24944232 http://dx.doi.org/10.1093/cid/ciu477 |
Ejemplares similares
-
Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV
por: Mahale, Prarthana R, et al.
Publicado: (2023) -
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
por: Ciccullo, Arturo, et al.
Publicado: (2019) -
Protocol for active safety monitoring of a cohort of patients using a dolutegravir-based antiretroviral regimen in Mozambique
por: Mussá, Merana, et al.
Publicado: (2021) -
Qualitative study exploring the experiences and perceptions of dolutegravir/lamivudine dual antiretroviral therapy (the PEDAL study) in people living with HIV: protocol
por: Villa, Giovanni, et al.
Publicado: (2022) -
Associations of HIV infection with insulin and glucose levels in antiretroviral-naïve Rwandan women: a cross-sectional analysis
por: Dusingize, Jean Claude, et al.
Publicado: (2013)